- Home
- / Corvus Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Corvus Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$8.9
2024-10-29
Market Capitalization
$556.1 M
2024-10-29
CreditSafe Score
?
Score changed on Jul 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2021 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 7.6M | 10.2M | 10.6M | 10.9M | 11.9M | 9.5M | 8.1M | 6.9M | 8.2M | 9.3M |
| Operating expense total | 37.0M | 56.5M | 49.2M | 48.9M | 43.8M | 32.6M | 27.5M | 43.0M | ||
| Depreciation and amortization | 105.0K | |||||||||
| EBIT | (37.0M) | (56.5M) | (49.2M) | (48.9M) | (43.8M) | (38.6M) | (32.6M) | (23.4M) | (27.5M) | (43.0M) |
| Investment income | 1.8M | 2.5M | ||||||||
| Pre tax profit | (36.4M) | (55.7M) | (46.9M) | (46.7M) | (6.0M) | (43.2M) | (41.3M) | (27.0M) | (59.1M) | (13.3M) |
| Net Income | (36.4M) | (55.7M) | (46.9M) | (46.7M) | (6.0M) | (43.2M) | (41.3M) | (27.0M) | (62.3M) | (15.3M) |
| EPS | (0.9) | (1.0) | (0.5) |